SEHK:2367Personal Products
Giant Biogene Holding (SEHK:2367) Margin Compression Tests Bullish Growth Narratives
Giant Biogene Holding (SEHK:2367) has posted fresh FY 2025 numbers, with first half revenue at C¥3.1b and basic EPS at C¥1.14, setting the stage against trailing 12 month revenue of C¥6.1b and EPS of C¥2.25. The company has seen revenue move from C¥2.5b in 1H 2024 to C¥3.1b in 1H 2025, while basic EPS shifted from C¥0.99 to C¥1.14 over the same periods, providing a clear view of how the top and bottom line are tracking into the latest release. With a trailing net profit margin of 34.7% versus...